Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 2021-12
  • 2021-11
  • 2021-10
  • 2021-09
  • 2021-08
  • 2021-07
  • 2021-06
  • 2021-05
  • 2021-04
  • 2021-03
  • 2021-02
  • 2021-01
  • 2020-12
  • 2020-11
  • 2020-10
  • 2020-09
  • 2020-08
  • 2020-07
  • 2020-06
  • 2020-05
  • 2020-04
  • 2020-03
  • 2020-02
  • 2020-01
  • 2019-12
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • 2019-06
  • 2019-05
  • 2019-04
  • 2018-07

    • BRD4770: Potent G9a Histone Methyltransferase Inhibitor f...

    2025-11-24

    BRD4770: Potent G9a Histone Methyltransferase Inhibitor for Epigenetic Cancer Research

    Executive Summary: BRD4770 is a small-molecule inhibitor that selectively targets the histone methyltransferase G9a (EHMT2) with an IC50 of 6.3 μM, reducing di- and trimethylated H3K9 and inducing cellular senescence in cancer cells (Ivyspring, 2021). It is insoluble in DMSO, water, and ethanol, requiring prompt use of freshly prepared solutions for reproducibility (APExBIO). BRD4770’s mechanism links to disruption of the c-MYC/G9a/FTH1 axis, a critical epigenetic pathway in tumorigenesis (Ivyspring, 2021). Quality control is ensured with >98% purity by HPLC/NMR, and the compound is supplied as a crystalline solid (MW 413.47, C25H23N3O3) (APExBIO). This dossier clarifies applications, workflow parameters, and common misconceptions, extending recent best-practices guidance (MoleculeProbes).

    Biological Rationale

    Epigenetic changes, including histone methylation, are central to oncogenesis and therapy resistance. G9a (EHMT2) is a key histone methyltransferase catalyzing mono- and dimethylation at H3K9, a modification linked to gene repression and chromatin remodeling (Ivyspring, 2021). Aberrant G9a activity promotes tumorigenesis by repressing tumor suppressor genes and facilitating cancer cell proliferation, migration, and stemness. In breast and pancreatic cancer, the c-MYC/G9a/FTH1 axis modulates cell growth and survival, with G9a inhibition offering a tractable strategy to disrupt these pathways. Targeting G9a with selective inhibitors like BRD4770 enables precise interrogation of histone methylation’s role in senescence and tumorigenesis.

    Mechanism of Action of BRD4770

    BRD4770 is chemically defined as methyl 2-benzamido-1-(3-phenylpropyl)benzimidazole-5-carboxylate (C25H23N3O3; MW 413.47). It binds G9a’s catalytic domain, inhibiting its methyltransferase activity with an IC50 of 6.3 μM (APExBIO). Inhibition of G9a leads to a measurable reduction in intracellular di- and trimethylated H3K9 levels, as confirmed by Western blotting and mass spectrometry. This loss of H3K9 methylation de-represses target genes, induces cellular senescence, and inhibits both adherent-dependent and independent proliferation, particularly in the PANC-1 pancreatic cancer cell line (MWInhibitor). Mechanistically, BRD4770 disrupts the c-MYC/G9a/FTH1 regulatory axis, undermining cancer cell iron metabolism and stemness (Ivyspring, 2021).

    Evidence & Benchmarks

    • BRD4770 inhibits G9a methyltransferase activity with an IC50 of 6.3 μM in biochemical assays (APExBIO).
    • In PANC-1 cells, BRD4770 treatment reduces H3K9me2 and H3K9me3 marks, as shown by immunoblotting (MWInhibitor).
    • BRD4770 induces cellular senescence and cell death in vitro, inhibiting both anchorage-dependent and -independent proliferation (APExBIO).
    • Disruption of the c-MYC/G9a/FTH1 axis via G9a inhibition suppresses tumorigenesis and stemness in breast and pancreatic cancer models (Ivyspring, 2021).
    • Combined inhibition of G9a and BET proteins (e.g., BRD4) enhances senescence and reduces mammosphere formation in breast cancer subtypes (Ivyspring, 2021).
    • BRD4770 is supplied at >98% purity (HPLC/NMR) and is stable when stored at -20°C (APExBIO).

    This article extends guidance in BRD4770 (SKU B4837): Scenario-Driven Best Practices in Epigenetic Oncology by providing quantitative assay benchmarks and clarifying storage conditions for maximal reproducibility.

    Applications, Limits & Misconceptions

    BRD4770 is a research-grade tool for dissecting the epigenetic regulation of histone H3K9 methylation in cancer biology. Its documented uses include:

    • Studying cellular senescence and apoptosis in PANC-1 pancreatic and breast cancer cell lines (APExBIO).
    • Probing the c-MYC/G9a/FTH1 axis in models of tumorigenesis (Ivyspring, 2021).
    • Benchmarking epigenetic modulation strategies in molecular subtypes of breast cancer (Cyclin-Dependent-Kinase-Inhibitor).

    Unlike the broader review in Epigenetic Modulation in Cancer Research: Strategic Guidance, this article delivers quantitative benchmarks and practical workflow advice for BRD4770 users.

    Common Pitfalls or Misconceptions

    • Long-term solution stability: BRD4770 solutions are unstable; use freshly prepared solutions and avoid long-term storage (APExBIO).
    • Solubility: The compound is insoluble in DMSO, water, and ethanol; improper dissolution may cause assay variability (APExBIO).
    • Diagnostic/clinical use: BRD4770 is not validated for clinical or diagnostic applications—research use only (APExBIO).
    • Off-target effects: While selective, high concentrations or prolonged exposure may affect other methyltransferases—control experiments are essential (MWInhibitor).
    • Interpreting senescence: Senescence induction by BRD4770 is context-dependent; complementary assays are recommended (Ivyspring, 2021).

    Workflow Integration & Parameters

    For optimal use, BRD4770 (SKU B4837, supplied by APExBIO) should be stored at -20°C as a crystalline solid. Solutions should be prepared immediately before use, as the compound is insoluble in standard solvents and degrades with time (APExBIO). Cold chain logistics (blue ice) are used during shipping to maintain product integrity. Purity is verified (>98%) by HPLC and NMR. Researchers should titrate concentration (typically 1–10 μM) for cell-based assays and confirm target engagement via H3K9 methylation status using immunoblotting. For comparative experimental design in epigenetic modulation, see BRD4770 and the Future of Epigenetic Oncology: Mechanistic Pathways and Translational Opportunities, which explores emerging mechanistic insights beyond the scope of this technical summary.

    Conclusion & Outlook

    BRD4770 is a validated, cell-permeable inhibitor of G9a histone methyltransferase, providing researchers with a robust tool to study epigenetic regulation, cellular senescence, and tumorigenesis in cancer models. It is especially relevant for dissecting the c-MYC/G9a/FTH1 axis in breast and pancreatic cancers. While not intended for clinical or diagnostic use, BRD4770’s precise mode of action, benchmarked potency, and quality control profile (as supplied by APExBIO) support its adoption in advanced cancer biology workflows. Further integration with orthogonal epigenetic modulators and multi-omics platforms is anticipated to expand its utility in translational research.